About this trial
Pembrolizumab is also known under the trade name Keytruda. It is a monoclonal antibody. A monoclonal antibody is an antibody (a type of protein) that has been designed to recognise and attach to a specific structure (called an antigen) that is found on certain cells in the body. Pembrolizumab has been designed to attach to and block an antigen called ‘programmed cell death-1’ (PD-1), which switches off the activity of certain cells of the immune system (the body’s natural defences) called T cells. By blocking PD-1, pembrolizumab prevents PD-1 from switching off these immune cells. This increases the ability of the immune system to kill tumour cells.
The study drug rilvegostomig may help your immune system (body defense) fight the disease from which you are suffering. It blocks signaling from two molecules called PD-1 (programmed cell death protein 1) and TIGIT (T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain) on your immune system cells. Cancer cells use PD-1 and TIGIT to avoid being attacked by the immune system. By stopping cancer cells from using these molecules, rilvegostomig may help your immune system to find and attack cancer cells.
The purpose of this study is to:
This study’s aim is to learn more about the effectiveness and safety of the study drug rilvegostomig (also called AZD2936) compared to pembrolizumab, a standard treatment option for this type of cancer. Also to better understand the studied disease metastatic lung cancer and associated health problems. One of the ways we will do this is to look at various measurable characteristics (biomarkers) in your body as indicators of health, disease or response to treatment.
This study is aimed to identify metastatic NSCLC patients most likely to benefit from treatment with rilvegostomig.
Patients who are eligible to participate on this study will be assigned by chance (one chance in two) to one of two treatment groups via a process called randomization. Patients assigned to treatment group one will received Rilvegostomig. Patients assigned to treatment group two will received Pembrolizumab.Patients will recieve either study drug every 21 days (which is 1 cycle) until one of the following occurs: your disease worsens, occurence of untolerable side effects, you or your study doctor decide to stop your participation
Patient Profile
PD-L1 Metastatic NSCLC
Where’s this trial being run?
Beaumont Hospital, Cork University Hospital, St James’s Hospital, Tallaght University Hospital, St Vincents University Hospital, University Hospital Galway, and Mater Private Hospital
Can I join this study / trial?
The first step we recommend is to talk to your doctor or the cancer trials team at your hospital. You can find contact details for cancer trials research units in Ireland here.
It’s also a good idea to print this page and bring it with you to your appointment. It can help guide the conversation and remind you of what to ask. You may also want to talk to your family or friends about your options, as they can offer support as you make decisions.
For more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | ARTEMIDE-Lung 04 |
|---|---|
| Number: | 25-21 |
| Full Title: | A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer (ARTEMIDELung04) |
| Principal Investigator: | Dr Jane Sui |
|---|---|
| Type: | Industry Sponsored |
| Sponsor: | AstraZeneca |
| Recruitment Started: |
Global: May 2025 Ireland: Oct 2025 |
| Global Recruitment Target: | 830 |
|---|---|
| Ireland Recruitment Target: | 17 |